Akebia Therapeutics (NASDAQ:AKBA) stock identified change of 124.08% away from 52-week low price and recently located move of -36.37% off 52-week high price. It has market worth of $914.01MM. AKBA stock has been recorded -14.73% away from 50 day moving average and 20.15% away from 200 day moving average. Moving closer, we can see that shares have been trading 2.53% off 20-day moving average.
On April 7, 2020, Akebia Therapeutics (NASDAQ:AKBA) a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, declared the appointment of Myles Wolf, M.D., M.M.Sc., to its Board of Directors, effective April 6. Dr. Wolf is a leading clinical nephrologist and physician-scientist in the fields of disordered mineral metabolism and cardiovascular disease in patients with chronic kidney disease (CKD). Dr. Wolf serves as Chief of the Division of Nephrology and a Professor of Medicine at Duke University School of Medicine.
We are thrilled to welcome Dr. Myles Wolf as a member of the Akebia Board of Directors, said Adrian Adams, Chairperson of the Board of Directors of Akebia. Given his extensive knowledge and experience with kidney and cardiovascular diseases, Myles brings valuable healthcare provider and patient perspectives to Akebia.
I share Akebia’s passion and commitment to advancing care of patients with kidney disease, said Dr. Wolf. I look forward to working with the other members of the Board and the management team to deliver on Akebia’s purpose to improve the lives of people living with kidney disease.
The Healthcare sector company, Akebia Therapeutics noticed change of -5.50% to $6.7 along volume of 1088955 shares in recent session compared to an average volume of 1.56M. The stock observed return of -11.61% in 5 days trading activity. The stock was at -16.77% over one month performance. AKBA’s shares are at -1.76% for the quarter and driving a -11.84% return over the course of the past year and is now at 6.01% since this point in 2018.
The average volatility for the week at 10.95% and for month was at 16.08%. There are 136.42M shares outstanding and 125.10M shares are floated in market. Right now the stock beta is 1.43.